Showing 1 to 10 of 40 Clinical Trials
|
CLINICAL TRIAL Trial No ClinicalTrials.gov ID |
Principal Investigator
Coordinator |
||
|---|---|---|---|
|
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
CIAG933A12101 NCT04857372  Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Mesothelioma Solid Tumors |
Dr. Marie Florescu Adeline Hamon 514-890-8000 poste 30737 |
|
Phase I Trial of PCLX-001 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies
PCLX-001-01 NCT04836195 Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Non-Hodgkin's Lymphoma Solid Tumors |
Dr. Rahima Jamal Adeline Hamon 514-890-8000 poste 30737 |
|
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial
CAPTUR/PM.1 NCT03297606 Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Solid Tumors |
Dr. Cristiano Ferrario Inna Zhylina 514-340-8222 poste 28437 |
|
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors
MK-7902-005 (LEAP-005) NCT03797326 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Solid Tumors |
Dr. Maxime Chénard-Poirier Véronique Jobin 418-525-4444 poste 15780 |
|
A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
MK-7339-002 NCT03742895 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Solid Tumors |
Dr. Pierre Dubé Leïla Idrissi Kaïtouni 514-252-3400 poste 5853 |
|
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
GARNET NCT02715284 Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Solid Tumors |
Dr. Vanessa Samouëlian Shirley Truchon 514-890-8000 poste 25350 |
|
A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Advanced Solid Tumours
FPX-01-01 NCT03746431 Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Solid Tumors |
Dr. Fred Saad Amal Nadiri 514-890-8000 poste 26074 |
|
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
GARNET NCT02715284 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Solid Tumors |
Dr. Lucy Gilbert Phuong-Nam (Nathalie) Nguyen 514-934-1934 poste 31975 |
|
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours
TROPION-PanTumor03 NCT05489211 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Solid Tumors |
Dr. Ramy Saleh Rodrigo Skowronski 514-934-1934 poste 36275 |
|
A Phase 1/2 Open-label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR444200-based Regimen in Participants With Advanced Solid Tumors.
TCD17240 NCT05450562 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Solid Tumors |
Dr. Maxime Chénard-Poirier Marie-Pierre Brochu 418-525-4444 poste 15768 |
Groupe d'étude en oncologie du Québec